STOCK TITAN

[Form 4] PAVmed Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Shaun O'Neil, Chief Operating Officer of PAVmed Inc. (PAVM), was granted 150,000 shares of restricted common stock on 09/30/2025 under the company’s Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The restricted shares carry a $0 purchase price and vest on May 20, 2028, and are subject to forfeiture if the required service period is not completed. After the grant, the reporting person beneficially owned 167,933 shares. The filing was reported on Form 4 and signed by power of attorney on 10/02/2025.

Shaun O'Neil, Chief Operating Officer di PAVmed Inc. (PAVM), è stato concesso 150,000 azioni ordinarie vincolate il 30/09/2025 ai sensi del sesto emendamento e riassetto del 2014 Long-Term Incentive Equity Plan della società. Le azioni vincolate hanno un prezzo di acquisto di $0 e vestono il 20 maggio 2028, e sono soggette a decadenza se non viene completato il periodo di servizio richiesto. Dopo l'assegnazione, la persona che riporta l'informazione deteneva beneficiariamente 167,933 azioni. La segnalazione è stata riportata nel modulo 4 e firmata per procura il 02/10/2025.

Shaun O'Neil, Chief Operating Officer de PAVmed Inc. (PAVM), recibió 150,000 acciones ordinarias restringidas el 30/09/2025 bajo el plan de acciones de incentivo a largo plazo enmendado y reformulado por sexta vez de 2014. Las acciones restringidas tienen un precio de compra de $0 y vencen el 20 de mayo de 2028, y están sujetas a perderse si no se completa el periodo de servicio requerido. Después de la adjudicación, la persona que reporta poseía beneficiosamente 167,933 acciones. La presentación se informó en el Formulario 4 y fue firmada por poder notarial el 02/10/2025.

Shaun O'Neil, PAVmed Inc. (PAVM)의 최고운영책임자(COO)로서 회사의 2014년 장기 인센티브 주식계획의 여섯 번째 수정 및 재정비에 따라 150,000 주의 제한 일반주를 2025-09-30에 지급받았으며, 제한 주식은 $0의 매수 가격을 갖고 2028년 5월 20일에 비로소 행사 가능해지며, 필요한 서비스 기간이 완료되지 않으면 몰수될 수 있습니다. 부여 후 보고자는 실질적으로 167,933 주를 소유하고 있습니다. 이 서류는 Form 4에 보고되었고 2025-10-02에 대리 서명으로 서명되었습니다.

Shaun O'Neil, Chief Operating Officer de PAVmed Inc. (PAVM), s’est vu accorder 150 000 actions ordinaires restreintes le 30/09/2025 dans le cadre du sixième Plan d’actionnaires à long terme révisé et reformulé de 2014. Les actions restreintes ont un prix d’achat de $0 et se vestent le 20 mai 2028, et sont susceptibles d’être perdues si la période de service requise n’est pas accomplie. Après l’attribution, la personne déclarant détenait bénéficairement 167 933 actions. Le dépôt a été reporté sur le Formulaire 4 et signé par procuration le 02/10/2025.

Shaun O'Neil, Chief Operating Officer von PAVmed Inc. (PAVM), erhielt 150.000 Stammaktien mit Einschränkungen am 30.09.2025 im Rahmen des sechsten geänderten und neu gefassten 2014 Long-Term Incentive Equity Plan des Unternehmens. Die eingeschränkten Aktien haben einen Kaufpreis von $0 und vesten am 20. Mai 2028 und können verfallen, wenn der erforderliche Dienstzeitraum nicht erfüllt wird. Nach der Zuteilung besaß die meldende Person vorteilhaft 167.933 Aktien. Die Einreichung wurde im Formular 4 gemeldet und am 02.10.2025 durch eine Vollmacht unterschrieben.

Shaun O'Neil
، المدير التنفيذي للعمليات في PAVmed Inc. (PAVM)، منح 150,000 سهماً عائداً مقيداً في 30/09/2025 وفقاً للخطة السادسة المعدلة والمنسوخة من Long-Term Incentive Equity Plan لعام 2014 الخاصة بالشركة. الأسهم المقيدة تحمل سعر شراء قدره $0 وتكتمل صلاحيتها في 20 مايو 2028، وتخضع لفقدانها إذا لم يتم استكمال فترة الخدمة المطلوبة. بعد المنح، امتلك الشخص المبلّغ عنه بشكل مستفيد 167,933 سهماً. تم الإبلاغ عن ملف الاستمارة 4 وتوقيعه بوكالة في 02/10/2025.

Shaun O'NeilPAVmed Inc. (PAVM)的首席运营官,被授予 150,000 股受限普通股,日期为 2025/09/30,依据公司第六次修订及重述的 2014 Long-Term Incentive Equity Plan。受限股票的购买价格为 $0,于 2028/05/20 授予生效,并如未完成所需的服务期限则可能被没收。授予后,汇报人实际持有 167,933 股。该披露在 Form 4 上报,并于 2025/10/02 由授权签字人签署。

Positive
  • 150,000 restricted shares granted to COO on 09/30/2025
  • Restricted shares vest on May 20, 2028, aligning executive incentives with long‑term performance
  • Reporting person beneficially owns 167,933 shares after the grant
Negative
  • None.

Insights

Insider equity grant signals alignment with shareholders through time‑based vesting.

The grant of 150,000 restricted shares to the COO ties compensation to continued service through May 20, 2028, which helps align management incentives with long‑term performance. The award is subject to forfeiture if the service requirement is not met, which is a common governance mechanism to retain executives and limit immediate dilution.

The award is a time‑vested equity grant at no cash cost to the recipient.

The restricted stock has a $0 purchase price and a single vesting date, indicating a retention-focused equity award rather than immediate cash compensation. The post‑grant beneficial ownership of 167,933 shares provides a concrete measure of the reporting person’s current stake.

Shaun O'Neil, Chief Operating Officer di PAVmed Inc. (PAVM), è stato concesso 150,000 azioni ordinarie vincolate il 30/09/2025 ai sensi del sesto emendamento e riassetto del 2014 Long-Term Incentive Equity Plan della società. Le azioni vincolate hanno un prezzo di acquisto di $0 e vestono il 20 maggio 2028, e sono soggette a decadenza se non viene completato il periodo di servizio richiesto. Dopo l'assegnazione, la persona che riporta l'informazione deteneva beneficiariamente 167,933 azioni. La segnalazione è stata riportata nel modulo 4 e firmata per procura il 02/10/2025.

Shaun O'Neil, Chief Operating Officer de PAVmed Inc. (PAVM), recibió 150,000 acciones ordinarias restringidas el 30/09/2025 bajo el plan de acciones de incentivo a largo plazo enmendado y reformulado por sexta vez de 2014. Las acciones restringidas tienen un precio de compra de $0 y vencen el 20 de mayo de 2028, y están sujetas a perderse si no se completa el periodo de servicio requerido. Después de la adjudicación, la persona que reporta poseía beneficiosamente 167,933 acciones. La presentación se informó en el Formulario 4 y fue firmada por poder notarial el 02/10/2025.

Shaun O'Neil, PAVmed Inc. (PAVM)의 최고운영책임자(COO)로서 회사의 2014년 장기 인센티브 주식계획의 여섯 번째 수정 및 재정비에 따라 150,000 주의 제한 일반주를 2025-09-30에 지급받았으며, 제한 주식은 $0의 매수 가격을 갖고 2028년 5월 20일에 비로소 행사 가능해지며, 필요한 서비스 기간이 완료되지 않으면 몰수될 수 있습니다. 부여 후 보고자는 실질적으로 167,933 주를 소유하고 있습니다. 이 서류는 Form 4에 보고되었고 2025-10-02에 대리 서명으로 서명되었습니다.

Shaun O'Neil, Chief Operating Officer de PAVmed Inc. (PAVM), s’est vu accorder 150 000 actions ordinaires restreintes le 30/09/2025 dans le cadre du sixième Plan d’actionnaires à long terme révisé et reformulé de 2014. Les actions restreintes ont un prix d’achat de $0 et se vestent le 20 mai 2028, et sont susceptibles d’être perdues si la période de service requise n’est pas accomplie. Après l’attribution, la personne déclarant détenait bénéficairement 167 933 actions. Le dépôt a été reporté sur le Formulaire 4 et signé par procuration le 02/10/2025.

Shaun O'Neil, Chief Operating Officer von PAVmed Inc. (PAVM), erhielt 150.000 Stammaktien mit Einschränkungen am 30.09.2025 im Rahmen des sechsten geänderten und neu gefassten 2014 Long-Term Incentive Equity Plan des Unternehmens. Die eingeschränkten Aktien haben einen Kaufpreis von $0 und vesten am 20. Mai 2028 und können verfallen, wenn der erforderliche Dienstzeitraum nicht erfüllt wird. Nach der Zuteilung besaß die meldende Person vorteilhaft 167.933 Aktien. Die Einreichung wurde im Formular 4 gemeldet und am 02.10.2025 durch eine Vollmacht unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
O'Neil Shaun

(Last) (First) (Middle)
360 MADISON AVENUE, 25TH FLOOR

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/30/2025 A 150,000(1) A $0(1) 167,933 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
/s/ Michael A. Gordon, by power of attorney 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for PAVmed (PAVM)?

The Form 4 was filed on behalf of Shaun O'Neil, the company's Chief Operating Officer.

What transaction is reported in the PAVmed Form 4?

A grant of 150,000 restricted shares of common stock was acquired on 09/30/2025 at a $0 price.

When do the restricted shares vest?

The restricted shares have a single vesting date of May 20, 2028 and are subject to forfeiture if the service period is not completed.

How many shares does the reporting person beneficially own after the transaction?

The filing reports beneficial ownership of 167,933 shares following the reported transaction.

Under which plan were the restricted shares granted?

The shares were granted under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan.
Pavmed

NASDAQ:PAVM

PAVM Rankings

PAVM Latest News

PAVM Latest SEC Filings

PAVM Stock Data

10.65M
18.02M
18.43%
10.64%
1.15%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK